Item 2.02 Results of Operations and Financial Condition.

On January 10, 2022, C4 Therapeutics, Inc. (the "Company") issued a press release announcing its key milestones for 2022. In the press release, the Company disclosed that its unaudited cash, cash equivalents, and marketable securities as of December 31, 2021 were approximately $450 million. A copy of the press release is furnished herewith as Exhibit 99.1.

The information contained in Item 2.02 of this Form 8-K is unaudited and preliminary and does not present all information necessary for an understanding of the Company's financial condition as of December 31, 2021 and its results of operations for the three months and year ended December 31, 2021. The audit of the Company's consolidated financial statements for the year ended December 31, 2021 is ongoing and could result in changes to the information set forth above.

Item 7.01 Regulation FD Disclosure.

The contents of Item 2.02 of this Current Report on Form 8-K are incorporated herein by reference.

The information in this Current Report on Form 8-K, including Exhibits 99.1 and 99.2 attached hereto, is being furnished and shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that Section, nor shall it be deemed subject to the requirements of amended Item 10 of Regulation S-K, nor shall it be deemed incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language in such filing. The furnishing of this information hereby shall not be deemed an admission as to the materiality of any such information.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits. The exhibits shall be deemed to be filed or furnished, depending on the relevant item requiring such exhibit, in accordance with the provisions of Item 601 of Regulation S-K (17 CFR 229.601) and Instruction B.2 to this form.



Exhibit
Number                                    Description
99.1        Press release issued January 10, 2022 (furnished herewith)
104       Cover Page Interactive Data File (embedded within the Inline XBRL document)

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses